The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
The Royal London One-Day Cup match being played in Cardiff has been abandoned due to a 'dangerous pitch'.
A series of crashes on the A470 have led to traffic disruption
A largely dry and warm afternoon, but a muggy night to come with showery outbreaks.